Good Morning Investors!!! Oil, yields, and a few key company updates are setting the tone again this morning, but the story has moved beyond simple market nerves. Crude is back above the level that gets inflation worries buzzing, while Treasury yields are maintaining pressure on housing and rate-sensitive stocks. At the same time, fresh results from companies tied to jobs and everyday business demand suggest parts of the economy are holding up better than feared. This morning’s jobless claims came in at 210,000, right in line with expectations and up slightly from 205,000 last week, reinforcing the idea that the labor market is cooling only gradually rather than cracking. That leaves the 1:00 PM ET 7-year Treasury auction as the next major test, while our company spotlight looks at a big AI chip move that shows just how much investors are still willing to pay for the next growth engine
|
Key Market Drivers
Oil’s Uncomfortable Climb: Brent crude pushed back around $107 a barrel in overnight trading, rising a decent amount overnight and pacing for a 44% jump this month. Markets in Japan, South Korea, and Hong Kong all traded lower in response. This follows another round of mixed signals regarding ceasefire talks, with U.S. and Iranian officials offering conflicting accounts while the Strait of Hormuz remains effectively blocked. The impact of this stretches far beyond airlines and oil producers. South Korea, for instance, is rolling out a 5 trillion won bond buyback alongside fuel tax cuts. This is a clear signal that rising energy costs are simultaneously hitting consumers, bond markets, and inflation expectations. The immediate test is simple: watch if Brent stays above $100 through early morning trading in the U.S. and if we get any verified shifts in diplomacy or shipping flows before the opening bell. 
Brent Oil, March 26, 2026
Bond Buyers Demand More Yield: The 10 year Treasury yield hovered near 4.36% in early trading, signaling something deeper than just a standard Federal Reserve storyline. On Wednesday, the Treasury’s $70 billion 5 year sale stopped at a 3.980% high yield, hot on the heels of Tuesday’s 2 year sale clearing at 3.936%. Recent trading in short dated notes has come with unusually heavy volume and wider bid ask spreads. This combination suggests investors are stressed and repositioning, rather than calmly accumulating long term assets. When bond markets get turbulent, borrowing costs climb, mortgage rates stay elevated, and the premium investors are willing to pay for future earnings usually falls, putting pressure on smaller companies and long-duration growth stocks. The next key test is the $44 billion 7-year note auction at 1:00 PM ET, especially after shaky demand in the 2-year and 5-year auctions earlier this week. Housing Feels the Rate Squeeze: The average 30 year fixed mortgage rate jumped to 6.43% last week, marking a 0.13 percentage point increase in just one week and a 0.34 point rise over three weeks. Unsurprisingly, mortgage applications dropped 10.5%. We’re seeing this pressure hit company guidance as well. KB Home reported first quarter revenue of $1.08 billion and a housing gross profit margin of 15.3% (down from 20.2% a year ago), alongside a lowered full year delivery target of 10,000 to 11,500 homes. This is critical because housing is one of the fastest conduits for higher yields to impact the real economy. While builders can temporarily offer incentives, expensive financing ultimately does the heavy lifting by squeezing monthly payments, which directly hurts builders, lenders, and housing related retailers. Watch if homebuilder stocks continue to slide after the open today and if mortgage rates remain stuck above 6.4% heading into next week. A Counterpoint to the Slowdown Narrative: While soft survey data has been pointing toward cooling growth, a few real economy companies just pushed back against that assumption. Paychex delivered $1.81 billion in revenue (beating the $1.79 billion expected) and adjusted earnings per share of $1.71 (vs. $1.67 expected). Cintas also raised its full year outlook following an 8.9% quarterly revenue increase to $2.84 billion. This doesn’t erase broader slowdown risks, but it does prove that segments of the labor and small business backdrop are bending rather than breaking. This trend is crucial for rate expectations: if basic workplace demand, compliance, and payrolls remain firm, the Fed has less wiggle room to ease rates, regardless of investor desires. This morning’s jobless claims came in at 210,000, exactly matching expectations and up only slightly from 205,000 last week, while continuing claims fell to 1.819 million. In plain English, layoffs still look low, which keeps the high-rate problem front and center rather than giving the market a clean slowdown signal. |
|
|
Diagnostic Testing Labs
Diagnostic testing labs operate as the quiet plumbing of the healthcare sector. They handle the blood work, cancer screens, genetic tests, and thousands of routine checks that guide doctors’ next steps. If you want a simple market proxy for the group, the SPDR S&P Health Care Services ETF (XHS) is a handy starting point, but the real focal point right now is the steadier demand for tests—even while geopolitics, rates, and oil hog the spotlight.
Diagnostic testing labs are still a useful defensive healthcare niche to understand, but this is better framed as a sector explainer than a fresh market-moving theme for today. Recent updates from Quest Diagnostics, Labcorp, and Sonic Healthcare were constructive, showing steady testing demand and ongoing outsourcing by hospitals, but those releases came in February, not this week. If you keep this section, present it as background on a steady part of healthcare rather than as one of the morning’s newest developments.
Quest Diagnostics (DGX):
One of the largest U.S. diagnostic information firms, Quest boasts a broad lab network with deep ties to employers, health plans, and hospital systems. Scale is their competitive edge; higher volume helps spread out fixed costs to keep margins steady. Management guided their 2026 adjusted earnings to $10.50 to $10.70 per share, beating consensus, while revenue guidance also topped expectations.
Labcorp (LH):
Labcorp mirrors Quest in routine diagnostics but features a second growth engine in biopharma lab services, offering more expansion avenues than a pure testing shop. This diverse mix acts as a great buffer when one segment slows down and the other picks up. They guided 2026 adjusted earnings to a better than expected $17.55 to $18.25 per share, following a 5.5% jump in diagnostics revenue in the latest quarter.
Sonic Healthcare (SHL.AX):
This is the global player to monitor. Operating imaging and pathology networks across Australia, Europe, and the U.S., Sonic uses a local lab model to compete effectively market by market rather than forcing a cookie cutter system everywhere. In their latest half year results, revenue rose to A$5.445 billion, organic growth was 5%, and radiology organic growth reached 7%.
InvestorsGrow Takeaway:
For everyday investors, the ultimate macro signal for this industry is the jobs market. When employment stays firm, more people keep their health insurance and continue visiting the doctor, which supports routine test volumes. Watch two main KPIs: organic test volume growth and revenue per requisition—essentially, how many tests are being run and how valuable that specific mix is. The biggest red flag here is reimbursement pressure, because price cuts from insurers or the government can hit margins incredibly fast. If volume is rising while pricing holds steady, this sector usually enjoys a decent tailwind.
Arm Holdings (ARM)
Arm develops the basic blueprints that power many of the world’s chips. Think of them as the architects of processors: they typically sell the plans and collect royalties rather than owning the full factory line.
In the past 24 hours, that script changed in a meaningful way. Arm unveiled its first in-house AI data-center chip, the AGI CPU, and the stock closed sharply higher on Wednesday after rising as much as 20% intraday. The move shows that investors are still willing to pay up for a credible new AI growth path.
ARM Holdings, March 26, 2026
Arm is up about 26.4% from its March 25, 2025 close, and roughly 208% above its $51 IPO price from September 2023, keeping in mind it hasn’t even been public for five full years. This perfectly summarizes the current investor mood in a single line: the market is more than willing to pay up when it sees a tangible AI growth path.
The reason this news landed with such an impact is simple. Arm historically relied on licensing its designs to giants like Nvidia and Qualcomm, but they are now targeting a larger slice of the value chain by selling finished chips into AI servers, putting them in direct competition with AMD and Intel. It’s a much bigger swing, and a riskier one, as it could supercharge growth but might also make some existing customers a little uneasy.
The number investors should be staring at is $15 billion. That’s Arm’s annual revenue target for this new chip in about five years—a massive leap compared to the roughly $4.91 billion Wall Street projects for the entire company this fiscal year. In plain English, Arm is telling the market this isn’t just a side project; they are actively trying to build a massive second engine. This ambition helps explain why the stock is trading at roughly 63 times forward earnings, easily dwarfing AMD’s 27x multiple.
Moving forward, monitor three key variables: whether Arm can start volume production on time in the second half of 2026, if clients beyond Meta and the initial first wave stick with the plan, and whether server revenue can genuinely begin to eclipse smartphone revenue. If that mix shift keeps improving, the bullish story gets much easier to believe. If they stumble, this recent rally might start to look like it had a bit too much espresso.
InvestorsGrow Takeaway:
Ultimately, what is really happening here is that Arm is attempting a major transition—moving from being the quiet landlord of the chip world to owning one of the loudest stores in the mall. The upside is clear, as surging AI server demand means Arm could capture significantly more revenue per win if their in house chip succeeds. Yet, the risks are equally apparent. It’s a move that costs more, introduces serious execution risk, and could strain relationships with clients who previously viewed Arm as neutral ground. For now, it’s a fascinating story about ambition scaling up incredibly fast.
